Homepage > Projects
Client
Year Date
Location
Category
The REVITRANE Cosmetics Registration Project marked a milestone as the Korean dermal filler brand registered its monophasic hyaluronic acid range in Dubai.Manufactured by BR Pharm Laboratory with KMFDS certification, REVITRANE’s five-formula portfolio HA10 Classic, Volume, Premium, Premium-Q, and Premium SUB-Q delivers 20mg/ml cross-linked HA with ultra-low BDDE residue across injection depths.
REVITRANE’s registration centered on verifying BR Pharm’s ISO-13485 manufacturing and CPMCPM (Cohesive Polydensified Matrix) technology. Dubai Municipality evaluated double cross-linking methodology achieving 93.4% viscosity retention while maintaining BDDE residue below 2ppm significantly lower than industry averages. Each formula’s particle size specification, from Classic’s ultra-fine gel to Premium SUB-Q’s largest particles, required depth-appropriate documentation.
Unlike single-formula competitors, REVITRANE offers practitioners precision tools for layered facial enhancement. Classic targets Russian lip techniques popular in Dubai’s cosmetic clinics, while Premium SUB-Q’s thick consistency sculpts cheekbones and jawlines sought in regional contouring trends. This tiered approach enables aesthetic doctors to customize treatments matching Dubai’s diverse facial anatomy and volumization preferences.
REVITRANE’s single-phase gel structure differentiates from older biphasic fillers through uniform intradermal distribution. The technology cross-linking at low temperature over extended periods creates malleable gels that spread evenly without particle aggregation. For Dubai practitioners transitioning from established brands, REVITRANE’s 27G/30G needle compatibility and 7-12 month longevity offer competitive performance through advanced Korean polymer chemistry.
